ReViral snags $44m Series C
ReViral Ltd., a clinical-stage biopharmaceutical company, has raised $44 million in Series C financing.
ReViral Ltd., a clinical-stage biopharmaceutical company, has raised $44 million in Series C financing.
Copyright PEI Media
Not for publication, email or dissemination